Skip to Content

Label Changes for:

Bentyl (dicyclomine hydrochloride, USP) Capsules/Tablets 10 mg, 20 mgBentyl (dicyclomine hydrochloride, USP) Injection 10 mg/mL

January 2013

Changes have been made to the WARNINGS, PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)


January 2013


5.3 Peripheral and Central Nervous System
  • Psychosis and delirium have been reported in patients sensitive to anticholinergic drugs (such as elderly patients and/or in patients with mental illness): signs and symptoms resolve within 12 to 24 hours after discontinuation of Bentyl


6.2 Post-marketing Experience
  • Psychiatric disorders: As with the other anti-cholinergic drugs, cases of delirium or symptoms of delirium such as amnesia (or transient global amnesia), agitation, confusional state, delusion, disorientation, hallucination (including visual hallucination) as well as mania, mood altered and pseudodementia, have been reported with the use of Dicyclomine. Nervousness and insomnia have also been reported.



August 2011



Inadvertent Intravenous Administration
  • Bentyl solution is for intramuscular administration only. Do not administer by any other route. Inadvertent intravenous administration may result in thrombosis, thrombophlebitis, and injection site reactions such as pain, edema, skin color change, and reflux sympathetic dystrophy syndrome.